Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacopeia Considers Splitting Accelrys from Drug Discovery Business

NEW YORK, July 12 - Pharmacopeia said Thursday that it is considering splitting its software business, Accelrys, off from its drug discovery businesses, as well as other strategic alternatives, to help the drug discovery operations expand independently of its collaborators and access a greater number of drug targets.

In addition to splitting its two core businesses, the company is also considering making acquisitions, or pursuing joint ventures to allow its drug discovery business to "reach its full potential," said Sue Rodney, Pharmocopeia's manager of investor relations.

Pharmacopeia made the announcment as it warned of a $1 million shortfall in second quarter 2001 revenues from its drug discovery business. The company said drug discovery revenues totaled about $6.8 million during the second quarter, and that its Accelrys software business earned revenues of about $19.5 million to $20 million. Pharmacopeia will announce its precise earnings August 1.

Rodney said that splitting Accelrys from its drug discovery business might "allow people to assign a more appropriate valuation to the two businesses." Currently, she said, investors value the combined company somewhere between a profit-oriented software company and drug discovery company with long-term revenue prospects. The company's shares closed yesterday at $19.55, down from a 52-week high of about $49.

But Pharmacopeia had more sanguine news about Accelrys. That part of the business saw revenue grow during the second at an annual rate of about 35 percent, in line with the company's expectations. 

In April, the company combined its four software subsidiaries, Molecular Simulations, Synopsys Scientific Systems, Oxford Molecular, and Genetics Computer Group, into Accelrys, and said that the new company would branch out into bioinformatics consulting services, in addition to developing software for life science applications. At the time, the company said the reorganization would allow the drug discovery part of the business to operate more efficiently.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more